Maravai Lifesciences Holdings, Inc.

SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2024 financial and operating results after the market closes on Thursday, November 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 9502421. The call will also be available via live or archived webcast on the “Investors” section of the Maravai web site at . About Maravai Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. CONTACT: Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@maravai.com

Medical Device Components (MDC) today named Corza Health CEO and Corza Medical founder Greg Lucier as its non-executive chairman, effective Oct. 1. “I’m thrilled to join the MDC team to shepherd continued growth and unlock additional value creation … as we help enhance the lives of patients around the globe by delivering unmatched medical components to the medical technology industry,” Lucier said in a post on LinkedIn. Nitinol Pulse: Sign up for our free nitinol email newsletter here San Diego-based MDC develops and manufactures miniature components for minimally invasive medical devices used in high-growth clinical specialties. It focuses on complex and high-precision components made from platinum group metals and nitinol. Johnson Matthey sold the business for $700 million to private equity firm Montagu this summer. Nitinol know-how and resources: What is nitinol and where is it used? Lucier was formerly CEO and chair of NuVasive, the spine surgery tech developer that merged with Globus Medical in 2023. Before that, he was chair and CEO of Life Technologies, growing the company’s annual revenue from around $700 million to nearly $4 billion, ultimately selling the business to Thermo Fisher Scientific in 2014 for around $15 billion. In 2019, Lucier founded healthcare investment firm Corza Health with the backing of private equity firm GTCR. In 2021, he and GTCR launched Corza Medical to develop ophthalmology, wound closure, biosurgery, and biomedical textile products. He’s now executive chair of Corza Medical, which ranked No. 94 on our 2024 Medtech Big 100 list of the largest medical device companies by revenue. Previously: Corza Medical set to take on ‘almost monopolistic’ surgical giants MDC said Lucier has been involved in more than 75 acquisitions worth more than $30 billion combined. He’s on the boards of directors for Catalent, Dentsply Sirona, Maravai Life Sciences, Antylia Scientific, Corza Medical and Pleno. “Greg brings a wealth of experience, having led transformative growth in the healthcare and medtech industries,” MDC said. “His strategic insights and leadership have consistently driven innovation and success, and we are excited about the vision and direction he will bring to our company.” Medical nitinol manufacturing: How this nickel-titanium alloy is made for medical devices

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in August and September. On August 14, 2024, at 11:00 a.m. PDT/ 2:00 p.m. EDT, Trey Martin, Chief Executive Officer, will participate in a panel discussion of the Critical Components of the Genomic Medicine Supply Chain at the UBS Genomic Medicine Conference in Dana Point, CA. On September 4, 2024, at 6:30 a.m. PDT/ 9:30 a.m. EDT, Trey Martin, Chief Executive Officer, and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the Wells Fargo Healthcare Conference in Boston, MA. On September 5, 2024, at 1:50 p.m. PDT/ 4:50 p.m. EDT, Trey Martin, Chief Executive Officer, and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Healthcare Conference in New York, NY. A live webcast of each presentation will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events, Upcoming events. An archived version of the webcast will also be available on the Maravai website after the event is completed. About Maravai Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies. For more information about Maravai LifeSciences, visit www.maravai.com. Contact Information: Investor Contact: Deb Hart Maravai LifeSciences +1 858-988-5917 ir@maravai.com